VR Logo

Tarsus Pharmaceuticals Inc. (TARS) download report


Healthcare | Biotechnology & Pharma Research

Tarsus Pharmaceuticals Inc. (TARS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.

IPO Date: 16-Oct-2020

Co-Founder & Independent Chairperson of the Board: Dr. D. Michael Ackermann Ph.D.

Co-Founder, Pres, CEO & Director: Dr. Bobak R. Azamian M.D.

Listing: NASDAQ: TARS

Country: United States

Headquarters: Irvine, CA

Website: https://www.tarsusrx.com

Key Facts

Market cap: $404.12 Mln

Revenue (TTM): $24.13 Mln

Earnings (TTM): $-44.44 Mln

Cash: $175.30 Mln

Total Debt: $20.41 Mln

Insider's Holding: 16.72%

Liquidity: Low

52 Week range: $10.80 - 31.00

Shares outstanding: 26,327,300

Stock Performance

Time Period Tarsus Pharmaceuticals (TARS) S&P BSE Sensex S&P Small-Cap 600
YTD-34.53-8.71-16.64
1 month2.58-3.11-6.45
3 months-15.05-7.30-12.22
1 Year-50.070.48-15.87
3 Years--10.347.51
5 Years--11.436.63
10 Years--12.1010.46
As on 28-Jun-2022
Year Tarsus Pharmaceuticals (TARS) S&P Small-Cap 600 S&P BSE Sensex
2021-45.5625.2721.99